Alterations in the ability of the bovine pituitary gland to secrete gonadotropins in vitro during the first follicle-stimulating hormone increase of the estrous cycle and in response to exogenous steroids.
The objective was to determine if the endocrine status of the animal dictates the responsiveness of gonadotrophs to estradiol, activin, inhibin and follistatin; hormones implicated in the differential release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Bovine pituitaries were obtained at 13 (n=8), 30 (n=24) and 66 (n=8) h after the onset of estrus, corresponding to before, during and the end of the first FSH increase of the estrous cycle which follows the pre-ovulatory gonadotropin surge in heifers. Heifers slaughtered at 30 h received no treatment, or were treated with progesterone with or without estradiol before slaughter to suppress the first transient FSH increase. Secretion of FSH from cultured pituitary cells, reflecting the prior in vivo status, was greater (P<0.01) at 30 h than 13 or 66 h, whereas, LH secretion was less (P<0.01) at 13 h compared with 30 h. Treatment with exogenous steroids decreased (P<0.05) the pituitary gland's ability to subsequently secrete FSH and LH. Inhibin and, to a greater extent, estradiol decreased (P<0.01) mean FSH secretion but increased (P<0.05) mean LH secretion. These findings suggest that estradiol and inhibin both have the ability to differentially modulate basal gonadotropin secretion during the first FSH increase of the bovine estrous cycle. Differential regulation of LH and FSH is mediated via an alteration in gonadotropin biosynthesis and basal secretion. Furthermore, the secretory capability of cultured pituitary cells and basal gonadotropin secretion reflect the prior endocrine status of the animal from which pituitaries were obtained.
Lane
E A
EA
Department of Animal Husbandry and Production, Faculty of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Padmanabhan
V
V
Roche
J F
JF
Crowe
M A
MA
D028341:Activins / Q000494:pharmacology; D000818:Animals; D019540:Area Under Curve; D002417:Cattle / Q000502:physiology*; D004958:Estradiol / Q000494:pharmacology; D030762:Estrous Cycle / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D004973:Estrus Synchronization / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000378:metabolism / Q000502:physiology*; D038681:Follistatin; D006062:Gonadotropins / Q000378:metabolism*; D007265:Inhibins / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D011897:Random Allocation; D013256:Steroids / Q000494:pharmacology*
D038681:Follistatin; D006062:Gonadotropins; D013256:Steroids; D028341:Activins; D004958:Estradiol; D007265:Inhibins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone